Drug Trial Radar · NCT01864746
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,250
Actual
Start
Oct 30, 2013
Primary completion
Aug 24, 2020
Study completion Dec 21, 2020
Sponsor
- Lead sponsor
- GBG Forschungs GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer; AGO Study Group; NSABP Foundation Inc; Breast International Group
- First posted
- May 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The PENELOPEB study is designed to demonstrate that, in the background of standard anti-hormonal therapy, palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women with HR-positive/HER2-normal early breast cancer at high risk of relapse after showing less than pathological complete response to neoadjuvant taxane- containing chemotherapy. Considering the high risk of recurrence in patients after neoadjuvant chemotherapy and a high CPS-EG score, palbociclib appears to be an attractive option with a favourable safety profile for these patients.
Conditions
- Breast Cancer
- Hormonreceptor Positive
- Her2-normal
- Postneoadjuvant Treatment With CDK 4/6 Inhibitor
- CPS-EG Score
Interventions
Palbociclib PD-0332991Drug
palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
PlaceboDrug
Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease Free Survival (iDFS) for Palbociclib vs. Placebo in Patients With High CPS-EG Score After Neoadjuvant Chemotherapy Receiving Standard Adjuvant Endocrine Therapy for HR-positive/HER2-normal Primary Breast Cancer.Time frame: From date of randomisation to data cut off: 24 August 2020 (approximately 6 years and 6 months)
Locations
11 sites in 11 countries. Site status is shown where the registry gives one.
NSABP Foundation
Pittsburgh, Pennsylvania
Contact: Australia and New Zealand Breast Cancer Trials Group
Newcastle, NSW 2310, Australia
Contact: Austrian Breast & Colorectal Cancer Study Group
Vienna, Austria
Contact: NSABP Foundation
Multiple Locations, Canada
Contact: UNICANCER
Paris, France
Contact: German Breast Group
Neu-Isenburg, Germany
Contact: Cancer Trials Ireland
Dublin, Ireland
Contact: Japan Breast Cancer Research Group
Tokyo, Japan
Contact: Korea Cancer Study Group
Seoul, South Korea
GEICAM
San Sebastián de los Reyes, Spain
Contact: Institute of Cancer Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.